Collegium Pharmaceutical Inc
COLL
Get informed when a big investor buys or sells
+ FollowMarket Cap$754.96M
Close$
$17.40
24% downside
Current Fair Value
24% downsideOvervalued by 24% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $754.96 Million |
|---|---|
| Enterprise Value | $1.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.98 |
| Beta | 0.73 |
| Outstanding Shares | 32,460,783 |
Return
| Return on Equity | 15.36% |
|---|---|
| Return on Assets | 2.24% |
| Return on Invested Capital | 15.13% |
Valuation & Multiples
| P/E Ratio | 15.16 |
|---|---|
| PEG | -6.72 |
| Price to Sales | 0.95 |
| Price to Book Ratio | 2.55 |
| Enterprise Value to Revenue | 1.84 |
| Enterprise Value to EBIT | 6.35 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.58 |
| Debt to Equity | 2.75 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.72
Average shareholder expectationRevenue Estimate
$199.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$1.86
Average shareholder expectationRevenue Estimate
$216.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 190.76% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.75%▼ 122.77% |
|---|---|
| Total Invested | $5.68M▼ 99.60% |
| Investors Holding | 13▼ 270.00% |
ESG Score
No data
About Collegium Pharmaceutical Inc
CEO: Joseph Ciaffoni